Antitrust Antitrust

Zhejiang Wepon's sales subsidiary fined in China for imposing unreasonable trading conditions

By MLex Staff
  • 18 Nov 2020 00:21
  • 18 Nov 2020 00:21
A sales subsidiary of Shenzhen-listed Wepon has been fined for imposing unreasonable trading conditions on the sale of the active pharmaceutical ingredient, or API, bromhexine hydrochloride.

Wepon Group Zhejiang Pharmaceutical Sales was fined 2,241,754 yuan ($341,960), equivalent to 3 percent of its revenue for 2019, and had 232,205 yuan in illegal gains

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News